ImmunityBio (IBRX) Shares Outstanding (Diluted Average) (2019 - 2026)

ImmunityBio (IBRX) has 8 years of Shares Outstanding (Diluted Average) data on file, last reported at $1.0 billion in Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $1.0 billion, up 20.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 20.36% YoY), and the FY2025 annual result was $919.9 million, up 31.33% from the prior year.
• Shares Outstanding (Diluted Average) advanced to $1.0 billion in Q1 2026 per IBRX's latest filing, from $919.9 million in the prior quarter.
• Over five years, Shares Outstanding (Diluted Average) peaked at $1.0 billion in Q1 2026 and troughed at $397.9 million in Q1 2022.
• A 5-year average of $632.6 million and a median of $672.8 million in 2024 frame the typical range for Shares Outstanding (Diluted Average).
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Diluted Average) gained 2.09% in 2022, then surged 58.67% in 2024.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $399.9 million in 2022, then rose by 27.19% to $508.6 million in 2023, then surged by 37.71% to $700.4 million in 2024, then jumped by 31.33% to $919.9 million in 2025, then grew by 11.63% to $1.0 billion in 2026.
• Business Quant data shows IBRX's Shares Outstanding (Diluted Average) at $1.0 billion in Q1 2026, $919.9 million in Q4 2025, and $896.3 million in Q3 2025.